EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)

BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • ALK rearrangement • MET exon 14 mutation • MET overexpression • ALK fusion • RET mutation • ROS1 fusion • ROS1 rearrangement • MET mutation • MET expression • RET rearrangement • NTRK fusion

docetaxel • Jiataile (sacituzumab tirumotecan) • bozitinib (APL-101)

Glumetinib combined with platinum-based chemotherapy for the treatment of MET-overexpressing locally advanced or metastatic non-small cell lung cancer: A single-arm, multicenter study (ChiCTR2600117342)

P1, N=48, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University

3 days ago

New P1 trial

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)

EGFR mutation • BRAF mutation • BRAF V600 • HER-2 mutation • RET fusion • MET overexpression • HER-2 exon 20 insertion • ALK fusion • RET mutation • ROS1 fusion • MET mutation • NTRK fusion

carboplatin • pemetrexed • Haiyitan (gumarontinib)

Clinical Activity of MET-TKIs in METex14 Skipping NSCLC With Poor Performance Status. (PubMed, Anticancer Res)

MET-TKIs are effective for NSCLC with the METex14 skipping mutation; however, their efficacy for patients with a poor PS is limited.

3 days ago

Retrospective data • Journal • PD(L)-1 Biomarker • IO biomarker

MET (MET proto-oncogene, receptor tyrosine kinase)

PD-L1 expression • MET exon 14 mutation

Tepmetko (tepotinib) • Tabrecta (capmatinib)

Balise: A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations (clinicaltrials.gov)

P2, N=168, Completed, Eli Lilly and Company | Active, not recruiting --> Completed

7 days ago

Trial completion

EGFR (Epidermal growth factor receptor)

EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X

erlotinib • emibetuzumab (LY2875358)

10d

SAVOIR: Savolitinib vs. Sunitinib in MET-driven PRCC. (clinicaltrials.gov)

P3, N=60, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2025 --> Dec 2026

10 days ago

Trial completion date

VHL (von Hippel-Lindau tumor suppressor)

VHL mutation

sunitinib • Orpathys (savolitinib)

10d

LUNG-MAP SUB-STUDY: Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial) (clinicaltrials.gov)

P2, N=56, Recruiting, SWOG Cancer Research Network | Trial completion date: May 2029 --> May 2028

10 days ago

Trial completion date

BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement

Cyramza (ramucirumab) • Tepmetko (tepotinib)

11d

Safety and Synergy of Capmatinib Plus Stereotactic Radiotherapy in MET Exon 14-Mutated Non-Small Cell Lung Cancer: A Case Report. (PubMed, Cureus)

He received capmatinib (800 mg/day) and denosumab, with SBRT to vertebral metastases and later to the primary lung tumor. Temporary suspension of capmatinib during SBRT, along with careful monitoring, optimized tolerability, and outcomes. This case supports the feasibility and potential synergy of precision multimodal therapy in MET-driven oligometastatic NSCLC, highlighting the need for further prospective studies.

11 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • MET (MET proto-oncogene, receptor tyrosine kinase) • NKX2-1 (NK2 Homeobox 1)

MET exon 14 mutation • MET mutation

Tabrecta (capmatinib) • Prolia (denosumab)

12d

SOUND: Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC (clinicaltrials.gov)

P2, N=47, Active, not recruiting, AstraZeneca | Trial completion date: Aug 2025 --> Jan 2027 | Trial primary completion date: Aug 2025 --> Jan 2027

12 days ago

Trial completion date • Trial primary completion date

MET (MET proto-oncogene, receptor tyrosine kinase)

MET amplification • EGFR wild-type • MET exon 14 mutation • MET overexpression • MET mutation

Imfinzi (durvalumab) • Orpathys (savolitinib)

12d

Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2) (clinicaltrials.gov)

P2, N=25, Recruiting, Jeeyun Lee | Trial completion date: Dec 2026 --> Jun 2027 | Trial primary completion date: Dec 2025 --> Dec 2026

12 days ago

Trial completion date • Trial primary completion date

MET (MET proto-oncogene, receptor tyrosine kinase)

MET amplification

Imfinzi (durvalumab) • Orpathys (savolitinib)

13d

Chemical Screening of RIKEN Natural Products Depository Identified a MYCN Expression Inhibitor Partially through HGF-MET Signaling Pathway. (PubMed, ACS Chem Biol)

Notably, MI102 effect exhibited superior tumor cell selectivity compared with the MET inhibitor tivantinib. At the transcriptional level, RNA-seq revealed that MI102 globally downregulated MYCN-associated oncogenic programs. Collectively, these findings establish pharmacological downregulation of MYCN as a promising therapeutic strategy for HCC and reveal a functional link between MET signaling and MYCN-driven oncogenic pathways.

13 days ago

Journal

MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • HGF (Hepatocyte growth factor)

MYCN expression

tivantinib (ARQ 197)

13d

A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN). (clinicaltrials.gov)

P2/3, N=84, Active, not recruiting, Beijing Pearl Biotechnology Limited Liability Company | Trial completion date: Dec 2024 --> Dec 2026

13 days ago

Trial completion date

cisplatin • temozolomide • etoposide IV • bozitinib (APL-101)

13d

Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)

P1/2, N=27, Active, not recruiting, Washington University School of Medicine | Recruiting --> Active, not recruiting | Trial completion date: May 2030 --> Dec 2029 | Trial primary completion date: Jun 2027 --> Jan 2027

13 days ago

Enrollment closed • Trial completion date • Trial primary completion date

EGFR (Epidermal growth factor receptor)

EGFR mutation

Tagrisso (osimertinib) • bozitinib (APL-101) • simmitinib (SYHA1817)